跳至主要内容
临床试验/NCT07140874
NCT07140874招募中2 期

Evaluation of Supplemental Zinc as an Adjunct to Prolong the Duration of Benefit After Botulinum Toxin Injections in Subjects With Cervical Dystonia

University of Florida1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2026年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
25
试验地点
1
主要终点
Duration of Botox efficacy

研究概览

简要总结

The goal of this clinical trial is to evaluate if supplemental zinc can prolong the duration of benefit of botulinum toxin injections in cervical dystonia patients receiving care at the University of Florida.

The main aims are:

  1. To evaluate the efficacy of zinc citrate supplementation in prolonging the duration of symptom relief provided by botulinum toxin type A (Botox) injections in cervical dystonia patients.
  2. To assess the safety and tolerability of zinc supplementation in this patient population.
  3. To analyze the potential influence of zinc supplementation on the quality of life and functional outcomes in cervical dystonia patients receiving Botox.

Researchers will compare zinc citrate to a placebo (a look-alike substance that contains no active drug) to see if zinc works to extend the effects of Botox.

Participants will:

Take zinc citrate or a placebo every day for 3 months, then cross over to the alternative treatment for another 3 months.

Visit the clinic every 3 months for Botox injections, check ups and surveys.

详细描述

Study Design:

  • Randomized, single-blind, crossover placebo-controlled trial.
  • Participants: Approximately 20 patients diagnosed with cervical dystonia and currently receiving botulinum toxin (BoNT) type A (Botox) injections at the University of Florida (UF) Movement Disorders Clinic with good response to treatment as determined by treating neurologist will be enrolled into this study. The investigators plan to screen 25 patients to allow for screen failures and withdrawals.
  • Intervention: Participants will be randomized to receive either zinc citrate 30 mg supplementation or placebo starting immediately after their scheduled BoNT injection for 3 months. At a follow up BoNT injection, they will receive the alternative treatment for another 3 months. The total observation period is 6 months. Standard time between BoNT injections is 3 months.

The UF Movement Disorders Clinic follows approximately 1,500 cervical dystonia patients a year. The investigators do not anticipate any recruitment challenges.

Participants will be recruited during neurology clinic appointments and screening clinic appointments.

  • Patients will receive the same pattern of BoNT injections (muscle selection and dose) during the duration of the study.
  • Blood serum levels of zinc and vitamin B12 and complete blood counts (CBCs) will be measured at baseline and at the end of the study. Participants will be sent to UF Health Medical lab for blood draws and sample collection.
  • Written informed consent will be obtained from each participant before any study-specific procedures or assessments are performed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adults aged 18-89 years.
  • •Diagnosed with cervical dystonia.
  • •Receiving regular BoNT type A (Botox) injections for at least six months.

排除标准

  • •Known allergy or intolerance to zinc.
  • •Significant comorbidities or concurrent medications that could interfere with study outcomes.
  • •Pregnant or breastfeeding women.
  • •Already taking a zinc supplement which would exceed tolerable upper intake level in adults (40 mg elemental zinc per day) with addition of zinc study supplement.

研究组 & 干预措施

Zinc first

Experimental

Encapsulated zinc citrate 30 mg orally daily for 3 months followed by placebo capsule matching zinc daily for 3 months

干预措施: Placebo (Drug)

Placebo first

Experimental

Placebo capsule matching zinc daily for 3 months, followed by encapsulated zinc citrate 30 mg orally daily for 3 months

干预措施: Placebo (Drug)

Zinc first

Experimental

Encapsulated zinc citrate 30 mg orally daily for 3 months followed by placebo capsule matching zinc daily for 3 months

干预措施: Zinc citrate (Drug)

Placebo first

Experimental

Placebo capsule matching zinc daily for 3 months, followed by encapsulated zinc citrate 30 mg orally daily for 3 months

干预措施: Zinc citrate (Drug)

结局指标

主要结局

Duration of Botox efficacy

时间窗: 3 and 6 months post intervention

Time to return to baseline symptom severity using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale. The TWSTRS Severity Subscale is scored from 0 to 35, with higher numbers indicating a more severe condition.

次要结局

  • Change in Pain Severity(3 and 6 months post intervention)
  • Change in Quality of Life(3 and 6 months post intervention)
  • Change in Functional Disability(3 and 6 months post intervention)
  • Patient Global Impression of Change(3 and 6 months post intervention)
  • Clinician Global Impression of Change(3 and 6 months post intervention)
  • Change in Pain Severity at 3 months(3 months post intervention)
  • Change in Quality of Life at 3 months(3 months post intervention)
  • Change in Functional Disability at 3 months(3 months post intervention)
  • Patient Global Impression of Change(3 months post intervention)
  • Clinician Global Impression of Change(3 months post intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验